Garadacimab is a fully human recombinant IgG4 monoclonal antibody that selectively binds to activated Factor XII (FXIIa) and inhibits its catalytic activity. It is developed for the prevention of recurrent attacks of hereditary angioedema (HAE). Garadacimab is also known by the development code CSL312 and is marketed as Andembry in approved markets.
Garadacimab is a specialized recombinant biological pharmaceutical ingredient belonging to the monoclonal antibody class. Unlike conventional small-molecule APIs, garadacimab requires recombinant biotechnology manufacturing, advanced purification and extensive biological characterization.
Development Code: CSL312
Molecule Type: Fully human recombinant monoclonal antibody
Antibody Class: IgG4 / Lambda
Target: Activated Factor XII (FXIIa and βFXIIa)
Pharmacologic Class: Activated Factor XII inhibitor
Therapeutic Area: Hereditary Angioedema / Hematology
ATC Code: B06AC07
Garadacimab binds to the catalytic domain of activated Factor XII (FXIIa and βFXIIa) and inhibits its activity. FXIIa is an important initiator of the kallikrein-kinin pathway. Blocking FXIIa prevents activation of prekallikrein to kallikrein and reduces generation of bradykinin, a key mediator responsible for vascular permeability and swelling during HAE attacks.
Garadacimab is indicated for the routine prevention of recurrent hereditary angioedema attacks in adults and adolescents aged 12 years and older in markets where it is authorized. The FDA review identifies garadacimab as a monoclonal antibody FXIIa inhibitor and describes its use for HAE prophylaxis.
HAE is associated with dysregulation of the kallikrein-kinin system and excessive bradykinin generation. By targeting FXIIa at an upstream point in this pathway, garadacimab suppresses the cascade responsible for bradykinin formation and helps prevent recurrent HAE attacks.
Garadacimab is a fully human IgG4/lambda recombinant monoclonal antibody. As a biological API, its quality assessment requires characterization of molecular identity, purity, aggregation, charge variants, potency and process-related impurities rather than the conventional small-molecule testing approach.
The approved regimen described by FDA and European product information is an initial 400 mg subcutaneous loading dose followed by 200 mg subcutaneously once monthly. Approved presentations include 200 mg/1.2 mL single-dose prefilled devices.
Garadacimab API quality evaluation may include:
Garadacimab should be stored under controlled refrigerated conditions according to the approved product information and validated stability data. The marketed product is supplied as a sterile solution for subcutaneous administration, and product-specific handling requirements should be followed.
Garadacimab represents a targeted biological approach to HAE prophylaxis by inhibiting FXIIa upstream of kallikrein and bradykinin formation. Structural studies have demonstrated its interaction with the catalytic region of βFXIIa and provide a molecular basis for its selective inhibitory activity.
Garadacimab is a fully human recombinant IgG4/lambda monoclonal antibody targeting activated Factor XII. It is also known as CSL312 and is used for routine prevention of recurrent HAE attacks in eligible patients. Its mechanism involves inhibition of FXIIa and subsequent reduction of bradykinin generation.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | NLT 98.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 5.5 – 6.5 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |